Protective Effect of FTY720 on Several Markers of Liver Injury Induced by Concanavalin A in Mice

Current Therapeutic Research - Clinical and Experimental

Volumn 73, Issue 4-5, 2012, Pages 140-149

  Yin, Xiao Dong ^a   Jia, Pei Jie ^a   Pang, Yan ^a   He, Jing Hua ^b  

^a TIANJIN UNION MEDICAL CENTER   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Concanavalin A; FTY720; Liver injury; Nuclear factor B; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CONCANAVALIN A; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; WESTERN BLOTTING;

EID: 84865550678     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2012.07.001     Document Type: Article

References (29)

1. Pfeilschifter W., Czech-Zechmeister B., Sujak M., et al. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med 2011, 3:2-7.
2. Coelho R.P., Payne S.G., Bittman R., et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007, 323:626-635.
3. Van der Boon R.M., Jardine J.D., Ottevanger B., et al. New developments in small molecule immunosuppressive drugs. Erasmus J Med 2011, 1:18-21.
4. Suzuki S. FTY720: Mechanisms of action and its effect on organ transplantation. Transplant Proc 1999, 31:2779-2782.
5. Yin N., Zhang N., Xu J., et al. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation 2011, 92:25-30.
6. Habicht A., Clarkson M.R., Yang J., et al. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol 2006, 176:36-42.
7. Kataoka H., Sugahara K., Shimano K., et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005, 2:439-448.
8. Ubai T., Azuma H., Kotake Y., et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res 2007, 27:75-88.
9. Idzko M., Hammad H., van Nimwegen M., et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006, 116:2935-2944.
10. Choi J.W., Gardell S.E., Herr D.R., et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011, 108:751-756.
11. Chiba K., Kataoka H., Seki N., et al. Fingolimod (FTY720), the sphingosine 1-phosphate receptor modulator, as a new therapeutic drug in multiple sclerosis. Inflammation and Regeneration 2011, 31:167-174.
12. He J.H., Zhang H.N., Lin Z.B. Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice. World J Gastroenterol 2005, 11:573-576.
13. Kuo C.F., Wang Y.H., Lei H.Y., et al. Concanavalin A protects mice from a lethal inoculation of intragastric Klebsiella pneumoniae and reduces the induced liver damage. Antimicrob Agents Chemother 2007, 51:3122-3130.
14. Chen L., Xie X.J., Ye Y.F., et al. Kupffer cells contribute to concanavalin A-induced hepatic injury through a Th1 but not Th17 type response-dependent pathway in mice. Hepatobiliary Pancreat Dis Int 2011, 10:171-178.
15. Crispe I.N. IL-17 in liver injury: an inflammatory issue?. Immunol Cell Biol 2012, 90:369-370.
16. Erhardt A., Wegscheid C., Claass B., et al. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J Immunol 2011, 186:5284-5293.
17. Sitia G., Iannacone M., Aiolfi R., et al. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog 2011, 7:e1002061.
18. Wolf D., Schumann J., Koerber K., et al. Low-molecular-weight hyaluronic acid induces nuclear factor-κB-dependent resistance against tumor necrosis factor-α-mediated liver injury in mice. Hepatology 2001, 34:535.
19. Sensken S.C., Bode C., Gräler M.H. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol Exp Ther 2009, 328:963-969.
20. Ni H.M., Chen X., Shi Y.H., et al. Genetic delineation of the pathways mediated by bid and JNK in tumor necrosis factor-alpha-induced liver injury in adult and embryonic mice. J Biol Chem 2009, 284:4373-4382.
21. Huo H.Z., Wang B., Liang Y.K., et al. Hepatoprotective and antioxidant effects of licorice extract against CCl(4)-induced oxidative damage in rats. Int J Mol Sci 2011, 12:6529-6543.
22. Cheung R., Shen F., Phillips J.H., et al. Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest 2011, 121:4446-4461.
23. Muriel P. NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol 2009, 29:91-100.
24. McKoy J.M., Angelotta C., Bennett C.L., et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007, 31:599-604.
25. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
26. DeLeve L.D., Wang X., Kanel G.C., et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003, 38:900-908.
27. Videla L.A. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J Hepatol 2009, 1:72-78.
28. Papa S., Bubici C., Zazzeroni F., et al. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem 2009, 390:965-976.
29. Luo D., Huang X., Liu B., et al. Role of glucocorticoid receptor and nuclear factor kappa B in rat hepatic injury after traumatic hemorrhagic shock. Afr J Pharm Pharmacol 2010, 4:865-873.